28-29 September 2023, Kragujevac, Serbia

www.iccbikg2023.kg.ac.rs

2nd International Conference on Chemo and Bioinformatics

ICCBIKG_2023

BOOK OF PROCEEDINGS
2nd International Conference on Chemo and BioInformatics
ICCBIKG 2023

BOOK OF PROCEEDINGS

September 28-29, 2023
Kragujevac, Serbia

Sponsored by
BSA binding of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid

Marina D. Kostić1*, Vera M. Divac2, Sven Mangelinckx3, Jovana S. Marjanović2

1 University of Kragujevac, Institute for Information Technologies, Department of Science, Kragujevac, Serbia e-mail: marinak@uni.kg.ac.rs
2 University of Kragujevac, Faculty of Science, Department of Chemistry, Kragujevac, Serbia; e-mail: vera.divac@pmf.kg.ac.rs, jovana.marjanovic@pmf.kg.ac.rs
3 Ghent University, Faculty of Bioscience Engineering, Department of Green Chemistry and Technology; e-mail: sven.mangelinckx@ugent.be

* Corresponding author

DOI: 10.46793/ICCB23.459K

Abstract: Herein, we present the results of the study devoted to the exploration of BSA binding of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid, as an example of constrained γ-amino dicarboxylic acid, and, taking into consideration that the effectiveness of a potential drug depends on its ability to bind to a protein carrier and in that way enable transfer through the blood stream. For the investigation of binding properties, we used the fluorescence emission titration of BSA with a synthesized compound. Considering that the BSA solution shows an intensive fluorescence emission around 360 nm, a decrease in emission intensity at λ = 366 nm with the addition of a solution of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid indicated the binding of the tested compound. According to the results obtained, our compound binds to the BSA in a molar ratio 1:1 (n ≈ 1). The optimal values of binding constant Ka are between $10^4$ and $10^6$ M$^{-1}$, which indicates to us that the Ka value of the tested compound is in the favorable range.

Keywords: amino acids, cyclopropanes, BSA

1. Introduction

The amino acids have gained important relevance in the research world particularly their unnatural counterparts as constituents of molecules with promising pharmaceutical potential [1]. The replacement of natural amino acids in peptides with non-proteinogenic examples has inspired the development of different studies directed to the better understanding of interactions of small molecules with biological targets such as enzymes or receptors [2, 3]. One of the most important fields in drug development is the design and synthesis of peptidomimetic molecules that should have the same pharmaceutical properties as their natural counterparts, but much better metabolic stability. For this purpose, one of the widely accepted methodologies is the use of conformationally constrained amino acids and dipeptides as entities that mimic parts of natural peptidic substrates and that enable us to understand the relationships between
peptide conformation and biological activity. All these circumstances have caused the
development of the synthetic methodologies devoted to the preparation of different examples of
conformationally constrained amino acids and their analogs [4]. The examples of rigid cyclic
amino acids have played an important role in therapeutic development due to their ability to,
upon incorporation into peptides or peptidomimetics, induce conformational restrictions and
enable significant structural effects [4]. Herein, we present the results of the in vitro study
devoted to the exploration of BSA binding of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic
acid 1 (Figure 1), as an example of sterically constrained amino acid derivatives and taking into
consideration that the effectiveness of a potential drug depends on its ability to bind to a protein
carrier and in that way enable transfer through the bloodstream.

2. Experimental section

2.1. Synthesis of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid

The synthesis of racemic 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid 1 was achieved
using the previously described procedure in the literature [5].

2.2. Albumin-binding studies

The protein-binding studies were made in accordance with the method described in the
literature [6-8].

3. Results and Discussions

Since the effectiveness of a potential drug depends on its ability to bind to a protein carrier,
which plays a key role in the transfer of substances through the blood stream, the binding
affinity of compound 1 to bovine serum albumin (BSA) has been examined.

![Emission spectra of BSA in the presence of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid.](image)

**Figure 1.** Emission spectra of BSA in the presence of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic
acid. [BSA] = 2 μM, [Acid]/[BSA] = 0-10, λex = 295 nm. Arrows show the intensity changes upon increasing
the concentrations of the examined compound.

For the investigation of binding properties, we used the fluorescence emission titration of
BSA with synthesized compounds. The spectra were observed in the range between 300 and 500
nm at an excitation wavelength of 295 nm. Considering that the BSA solution shows an
intensive fluorescence emission around 360 nm, at the mentioned wavelength [9], decrease in emission intensity at λ = 366 nm (Figure 1) with the addition of a solution of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid indicated binding of tested compound to the BSA molecule.

**Figure 2.** left: Plots of $I_0/I$ versus $[Q]$ in mol/dm$^3$; right: lots of log($I_0-I/I$) versus log $[Q]$.

The fluorescence quenching data such as Stern-Volmer constant ($K_{sv}$) were defined from the linear dependence of $I_0/I$ to the concentration of the tested compound (Figure 2, left) using the Stern-Volmer quenching equation and number of binding sites per BSA molecule ($n$) were acquired by using the Stern-Volmer equation (1)

$$ \frac{I_0}{I} = 1 + K_{sv}[Q] \quad (1) $$

where $I_0$ and $I$ are the emission intensities in the absence and in the presence of the quencher (tested compound), $[Q]$ is the quencher’s concentration.

Binding constant ($K_a$) can be calculated from the equation 2, which represents the relationship between fluorescence quenching intensity and the concentration of quencher [8]

$$ \log \left( \frac{I_0 - I}{I} \right) = \log K_a + n \cdot \log [Q] \quad (2) $$

where $n$ is the number of binding sites per BSA. The value for $K_a$ can be calculated through the linear dependence of log $[(I_0 - I)/I]$ versus log $[Q]$ (Figure 2, right), where $K_a$ can be calculated from the slope, while the $n$ represents the intercept.

The calculations of all parameters were performed, and the obtained values are presented in Table 1.

**Table 1.** Binding parameters ($K_{sv}$, $K_a$, $n$) and the correlation coefficient ($R$) for interactions of the tested compound with BSA.

<table>
<thead>
<tr>
<th>Acid 1</th>
<th>$10^4K_{sv}$ BSA (M$^{-1}$)</th>
<th>$K_a$ [M$^{-1}$]</th>
<th>$R$</th>
<th>$n$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid 1</td>
<td>5.7 ± 0.1</td>
<td>$1.8 \times 10^5$</td>
<td>0.99</td>
<td>1.02</td>
</tr>
</tbody>
</table>
If we look at the Ka value in Table 1, we can conclude that the tested compound has a very good binding affinity to BSA molecules, knowing that the optimal values of binding constant Ka are between $10^4$ and $10^6$ M$^{-1}$ [9]. Also, we can conclude that our compound binds to the BSA in molar ratio 1:1 (n $\approx$ 1). The optimal values of binding constant Ka are between $10^4$ and $10^6$ M$^{-1}$ [9], which indicates to us that the Ka value of the tested compound is in the favorable range.

4. Conclusions

According to the results obtained in the screening of binding affinity of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid toward BSA, we can conclude that our compound has a very good binding affinity toward BSA molecules and that it binds to the BSA in molar ratio 1:1.

Acknowledgment

This research is funded by the Ministry of Education and Ministry of Science, Technological Development and Innovation, Republic of Serbia, Grants: (Agreement No. 451-03-47/2023-01/200122 and 451-03-47/2023-01/200378).

References